Top Viagra Brands for Men: Your Ultimate Guide

Viagra, a popular medication used for the treatment of erectile dysfunction, has seen a multitude of brands offering their own formulations over the years. Each brand aims to provide its unique take on the efficacy, delivery method, and affordability of this renowned medication. From well-established pharmaceutical giants to innovative newcomers, the market offers a diverse range of options for those seeking effective solutions. To explore the top brands that have garnered considerable acclaim and trust for their quality and results, see the detailed list below.

Illustration of viagra for men

Best brands of viagra for men in 2025

Pfizer

Pfizer's Viagra remains a dominant force in the erectile dysfunction market despite intense generic competition, with the brand maintaining a significant market share even after losing patent exclusivity. In 2020, Viagra reported a 29% increase in Q3 global sales, driven by strong performance in China and other international markets, accounting for 79% of its Q3 sales. The brand's resilience is attributed to Pfizer's strategic marketing, introduction of an authorized generic version, and robust discount programs, allowing it to capture a portion of the generic market while retaining brand-loyal consumers. As of 2024, the Viagra segment still dominates the erectile dysfunction drugs market with a 57.3% revenue share. Pfizer's strategic efforts have enabled Viagra to maintain its market position, a rare feat for a branded pharmaceutical product post-patent expiration. For more insights, explore the detailed analysis on Viagra's Q3 sales performance and competition.

Teva Pharmaceuticals

Teva Pharmaceuticals' generic version of Viagra, known as Teva sildenafil, is a highly effective and cost-efficient treatment for erectile dysfunction, holding a significant market share since its launch in 2017. This medication, which contains the same active ingredient as Viagra, sildenafil citrate, has been approved by the FDA and is bioequivalent to the branded version, making it a popular choice for men. Teva sildenafil is prescribed to improve blood flow and inhibit the PDE5 enzyme, with a recommended dosage of 50 mg that can be adjusted up to 100 mg as needed. The availability of Teva sildenafil has contributed to the growth of the erectile dysfunction treatment market, with Viagra and its generics dominating the market with a share of up to 57.3% in 2024.

Mylan

Mylan is not a producer of Viagra, but it is one of the key players in the Vardenafil Hydrochloride Trihydrate API market, which is used in the production of generic Levitra. Vardenafil, the active ingredient in Levitra, is a PDE5 inhibitor used to treat erectile dysfunction and is less popular than Viagra or Cialis but still a significant option. The global Vardenafil Hydrochloride Trihydrate API market, which includes Mylan, was valued at approximately USD 1.2 billion in 2023 and is projected to grow. Mylan, along with other companies like CHROMO LABORATORIES INDIA PRIVATE LTD and ALEMBIC PHARMACEUTICALS LTD, contributes to the market's growth through their API production. Vardenafil costs around $15-$19 per pill without insurance, making it a more expensive option compared to sildenafil and tadalafil.

Cipla

Cipla's Suhagra, a generic version of Viagra, is a highly effective treatment for erectile dysfunction, offering efficacy and active components similar to Viagra. Available in 25mg, 50mg, and 100mg doses, Suhagra is priced affordably, with a 100mg pill costing around $0.37 in India and between $0.50 to $5 online. This medication, like other sildenafil-based drugs, dominates the market with Viagra (sildenafil citrate) holding a 57.3% revenue share in 2024. Cipla's sildenafil products are approved by regulatory bodies such as the MCC in South Africa, ensuring their safety and efficacy. The global erectile dysfunction drugs market, led by such generic versions, is expected to grow at a CAGR of 6.8% from 2023 to 2032. For a detailed overview, visit the encyclopedia entry.

Sun Pharmaceuticals

Sun Pharmaceuticals, through its brand Silagra, is a significant player in the sildenafil market, offering a generic version of Viagra that is widely accepted due to its affordability and effectiveness. Silagra, containing sildenafil citrate, holds a substantial market share in the erectile dysfunction drugs market, with generics like Silagra accounting for the largest market share due to their lower cost and increasing demand globally. The sildenafil drug market, which includes Silagra, is expected to grow at a CAGR of 6.7% from 2023 to 2030, reaching a market size of US$ 4.56 billion by 2030. In 2022, the erectile dysfunction drugs market, dominated by sildenafil citrate, was valued at USD 3.2 billion, with sildenafil citrate holding a 58% revenue share. The growing geriatric population and increasing awareness about ED treatment options are key drivers of this market growth.

Lupin Pharmaceuticals

Lupin Pharmaceuticals is a significant player in the erectile dysfunction drugs market, particularly with its brand Penegra, which is a generic version of Viagra (sildenafil citrate). Penegra has been available since the expiration of Pfizer's patent on Viagra, allowing Lupin to capitalize on the demand for affordable erectile dysfunction treatments. The Viagra segment, including generic versions like Penegra, held a dominant market share of around 57.3% in 2024. Lupin's entry into this market has been strategic, leveraging the global demand for erectile dysfunction drugs, which is expected to grow at a CAGR of 6.8% from 2022 to 2032. This growth is driven by increasing incidence of erectile dysfunction and the rise in psychological disorders such as stress, depression, and anxiety.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a prominent producer of generic Viagra, known for its high-quality and effective sildenafil citrate tablets. The company's sildenafil product is indicated for adult men with erectile dysfunction, with a recommended dose of 50 mg that can be adjusted to 100 mg or 25 mg based on efficacy and tolerability. In 2019, Dr. Reddy's launched several new products, including Tadalafil (Adcirca and Cialis), contributing to their robust growth in the pharmaceutical market. The global erectile dysfunction drugs market, dominated by Viagra and its generics, is expected to grow at a CAGR of 9.13% from 2025 to 2030, with Viagra holding a significant market share of 57.3% in 2024. Dr. Reddy's strong presence in this market is driven by their extensive product portfolio and strategic launches.

Ajanta Pharma

Ajanta Pharma, the manufacturer of Kamagra, is a prominent producer of erectile dysfunction treatments, particularly known for its Kamagra Oral Jelly which contains the active ingredient sildenafil citrate, the same as in Viagra. Kamagra Oral Jelly is distinguished by its jelly-like consistency, offering faster absorption and ease of use. Ajanta Pharma is based in India and has a significant global presence, with India accounting for 98% of the total global Kamagra Oral Jelly exports. The company has shown strong performance, with a 12% increase in revenue from operations in Q1 FY 2025 compared to the previous year. However, it is crucial to note that Kamagra is not approved by the FDA and is often sold without prescription, posing safety risks.

Zydus Cadila

Zydus Cadila, through its brand Tadacip, is a prominent producer of tadalafil, a medication used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. In March 2024, Zydus Lifesciences received final approval from the US FDA to commercialize its Finasteride and Tadalafil Capsules, which will enjoy 180 days of exclusivity in the US market. The company's tadalafil products are available in various strengths, including 2.5 mg, 5 mg, 10 mg, and 20 mg, and are manufactured at their plant in Moraiya, Ahmedabad. Zydus Cadila's domestic sales have shown significant growth, with an 11.2% increase in February 2024, driven by key brands like Lipaglyn and Amicin. The company's focus on complex products and specialty drugs is expected to drive further growth. For more detailed information, visit their official website.

Torrent Pharmaceuticals

Torrent Pharmaceuticals, through its brand Tadora, is a significant player in the erectile dysfunction drugs market, particularly with its generic version of Viagra (sildenafil citrate). In 2024, the Viagra segment, which includes generic versions like Tadora, dominated the market with a 57.3% revenue share. Torrent Pharmaceuticals is known for its global presence, operating in over 50 countries, and holds the largest market share among Indian companies in Brazil and Germany. The company's strategic initiatives and partnerships have contributed to the expansion of its product portfolio, including erectile dysfunction treatments. The global erectile dysfunction drugs market, driven by such generic versions, is expected to grow at a CAGR of 9.13% from 2025 to 2030.